Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
Phase 1 Completed
44 enrolled
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
Phase NA Completed
1 enrolled
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
Phase NA Completed
2 enrolled
Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
Phase 4 Completed
6 enrolled
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
Phase NA Completed
2 enrolled
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
Phase 2 Unknown
20 enrolled
Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
Phase NA Withdrawn
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
Phase NA Completed
1 enrolled
Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment
Phase 1 Completed
15 enrolled
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
Phase 1 Completed
48 enrolled
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
Phase 1 Completed
48 enrolled
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
Phase 2 Completed
15 enrolled